GSK-49653/183

Study Sponsor: GSK

Study Title

A 24 Week Randomized, Double-blind, Double-dummy, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Avandia™ XR and AVANDIA™ (4mg BD) in Patients with Type 2 Diabetes

Medicine or Vaccine (generic name)

rosiglitazone

Sponsor Identification Number

49653/183

Trial Registry Identification Number(#'s)

Medical Condition

Diabetes Mellitus, Type 2

Phase

Phase 3

Link to GSK Study Register

http://www.gsk-clinicalstudyregister.com/study/49653/183

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report

Additional information about the data and documents available for this study

A link to Clinicaltrials.gov and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.

Date Added to this Site

February 2015